Want to see ES:ALM full AI Analyst Report?
ALM Stock Chart & Stats
€11.26
€0.12(1.07%)
At close: 4:00 PM EDT
€11.26
€0.12(1.07%)
Day’s Range― - ―
52-Week Range€10.06 - €13.98
Previous CloseN/A
Volume17.72K
Average Volume (3M)106.20K
Market Cap
€2.44B
Enterprise Value€2.41K
Total Cash (Recent Filing)€355.41M
Total Debt (Recent Filing)€321.35M
Price to Earnings (P/E)33.5
Beta0.64
Next Earnings
Nov 09, 2026EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend Yield1.66%
Share Statistics
EPS (TTM)0.33
Shares Outstanding217,777,330
10 Day Avg. Volume134,753
30 Day Avg. Volume106,204
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)1.85
Price to Sales (P/S)2.49
P/FCF Ratio20.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.39
Revenue Forecast (FY)€1.23B
Bulls Say, Bears Say
Bulls Say
TTM Revenue Rebound & Return To ProfitabilityThe recent TTM rebound where revenue accelerated sharply and Almirall returned to profitability indicates the core dermatology portfolio can scale and support sustainable operating earnings. This durable improvement strengthens the firm's ability to fund R&D, commercial expansion, and reduce reliance on one-off gains, improving medium-term cash generation and operational footing.
Conservative, Improving Balance SheetDeclining debt-to-equity and rising equity provide Almirall with lasting financial flexibility. A conservative leverage profile reduces refinancing and solvency risk, enabling steady investment in product launches, inorganic opportunities, or shareholder returns without materially increasing financial strain over the next several quarters.
Strong TTM Operating & Free Cash FlowRobust operating and free cash flow in the TTM period demonstrates the business is currently generating cash to fund operations and reinvestment. Sustainable cash generation supports durable capital allocation choices—R&D, marketing, or debt paydown—which underpin long-term competitiveness if cash conversion remains stable.
Bears Say
Multi-year Earnings VolatilityHistoric swings from losses to modest profits reduce confidence that recent gains will persist. Such volatility complicates planning, makes forecasting and consistent investment harder, and raises the risk that temporary wins may reverse, limiting the firm's ability to deliver predictable long-term returns to shareholders.
Inconsistent Free Cash Flow HistoryEpisodes of negative or breakeven free cash flow in prior years show cash generation is not yet reliably durable. This inconsistency can force reliance on external financing or delayed investments during weak periods, restricting the company's capacity to sustain R&D, commercialization, or dividend policies across economic cycles.
Low Returns On Shareholder CapitalMid-single-digit returns indicate the company currently earns limited excess on its capital base. Persistently low ROIC constrains value creation and suggests either limited pricing power, competitive pressure in dermatology, or inefficiencies in capital deployment—factors that can cap long-term shareholder upside absent structural improvement.
Almirall News
ALM FAQ
What was Almirall SA’s price range in the past 12 months?
Almirall SA lowest stock price was €10.06 and its highest was €13.98 in the past 12 months.
What is Almirall SA’s market cap?
Almirall SA’s market cap is €2.44B.
When is Almirall SA’s upcoming earnings report date?
Almirall SA’s upcoming earnings report date is Nov 09, 2026 which is in 100 days.
How were Almirall SA’s earnings last quarter?
Almirall SA released its earnings results on Jul 24, 2026. The company reported €0.112 earnings per share for the quarter, missing the consensus estimate of €0.13 by -€0.018.
Is Almirall SA overvalued?
According to Wall Street analysts Almirall SA’s price is currently Overvalued.
Does Almirall SA pay dividends?
Almirall SA pays a Annually dividend of €0.184 which represents an annual dividend yield of 1.66%. See more information on Almirall SA dividends here
What is Almirall SA’s EPS estimate?
Almirall SA’s EPS estimate is 0.13.
How many shares outstanding does Almirall SA have?
Almirall SA has 217,777,330 shares outstanding.
What happened to Almirall SA’s price movement after its last earnings report?
Almirall SA reported an EPS of €0.112 in its last earnings report, missing expectations of €0.13. Following the earnings report the stock price went up 1.266%.
Which hedge fund is a major shareholder of Almirall SA?
Currently, no hedge funds are holding shares in ES:ALM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Almirall Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.76%
12-Months-Change
Fundamentals
Return on Equity
1.66%
Trailing 12-Months
Asset Growth
-2.48%
Trailing 12-Months
Company Description
Almirall SA
Almirall, S.A. is a biopharmaceutical firm dedicated to the discovery, development, production, and commercialization of treatments primarily focused on skin health. Operating globally, with a significant presence in Europe and the United States, its product line targets various dermatological ailments such as actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, and acne, alongside rare skin conditions. Beyond its core dermatology focus, the company also offers solutions for cardiovascular, musculoskeletal, respiratory, and nervous system disorders, as well as products for digestive health, anti-infectives for systemic use, genitourinary conditions and sex hormones, immunostimulants, and systemic hormonal preparations. Its extensive portfolio includes a range of well-known medications, such as Ilumetri, Solaraze, Skilarence, and Klisyri, among others. Almirall fosters strategic partnerships with numerous entities to advance its pipeline, including research institutions like the University of Dundee and commercial partners such as Eli Lilly and Company. Founded in Barcelona, Spain, in 1943, the company adopted its current name, Almirall, S.A., in May 2009, having previously been known as Laboratorios Almirall, S.A.